03. Mai 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

03.05.2019 / 14:38
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Natural person (first name, surname): Ari Zweiman
Date of birth: 15 Apr 1972

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

02 Nov 2018

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	2.90 %	0.85 %	3.75 %	36021540
Previous notification	3.75 %	0.00 %	3.75 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1043443	0.00 %	2.90 %
Total	1043443		2.90 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
right to recall re-hypothecated shares		at any time	306557	0.85 %
		Total	306557	0.85 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
					%
			Total		%

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Ari Zweiman	%	%	%
683 Capital GP, LLC	%	%	%
683 Capital Partners, LP	%	%	%

Ari Zweiman	%	%	%
683 Capital Management, LLC	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

30 Apr 2019

03.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

02. Mai 2019

Epigenomics AG: CMS akzeptiert Epigenomics‘ Antrag auf NCD-Überprüfung

Epigenomics AG / Schlagwort(e): Sonstiges
Epigenomics AG: CMS akzeptiert Epigenomics‘ Antrag auf NCD-Überprüfung

03.05.2019 / 00:40 CET/CEST
Veröffentlichung einer Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch DGAP – ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

CMS akzeptiert Epigenomics‘ Antrag auf NCD-Überprüfung

Berlin, 3. Mai 2019 – Die Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; das „Unternehmen“) gibt bekannt, dass die Centers for Medicare & Medicaid Services (CMS) den Antrag des Unternehmens für eine Überprüfung einer National Coverage Determination (NCD) von Epi proColon, dem Bluttest von Epigenomics zur Darmkrebsvorsorge, angenommen haben. Die NCD ist eine der beiden Optionen, um eine CMS-Erstattung für Epi proColon zu erhalten, was für das Unternehmen einen wichtigen Durchbruch auf dem US-Markt bedeuten würde.

Die CMS haben den Antrag akzeptiert, werden den NCD-Prüfungsprozess aber aufgrund begrenzter personeller Ressourcen nicht unmittelbar beginnen können. Sobald die CMS ausreichend Kapazitäten zur Verfügung haben, wird die NCD mit einer 30-tägigen Periode zur öffentlichen Kommentierung „eröffnet“. Anschließend müssen die CMS per Statut innerhalb von sechs Monaten einen Entscheidungsvorschlag bekannt geben. Wenn dieser Vorschlag positiv ist, folgt eine weitere 30-tägige Kommentierungsfrist. Eine endgültige Entscheidung über die Erstattungsübernahme wird die CMS dann innerhalb von 90 Tagen nach dem ersten Entscheidungsvorschlag veröffentlichen.

Kontakt:
Unternehmen
Epigenomics AG, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

03.05.2019 CET/CEST Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de

Sprache:	Deutsch
Unternehmen:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Deutschland
Telefon:	+49 30 24345-0
Fax:	+49 30 24345-555
E-Mail:	ir@epigenomics.com
Internet:	www.epigenomics.com
ISIN:	DE000A11QW50
WKN:	A11QW5
Börsen:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart, Tradegate Exchange
EQS News ID:	806789


Ende der Mitteilung	DGAP News-Service

23. April 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

23.04.2019 / 09:43
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

15 Apr 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	0.00 %	0.09 %	0.09 %	36021540
Previous notification	3.34 %	0.09 %	3.44 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	0	0.00 %	0.00 %
Total	0		0.00 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	33619	0.09 %
		Total	33619	0.09 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

18 Apr 2019

23.04.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

23. April 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

23.04.2019 / 09:43
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

15 Apr 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	0.00 %	0.09 %	0.09 %	36021540
Previous notification	3.34 %	0.09 %	3.44 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	0	0.00 %	0.00 %
Total	0		0.00 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	33619	0.09 %
		Total	33619	0.09 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

18 Apr 2019

23.04.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

02. April 2019

DGAP-DD: Epigenomics AG deutsch

Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen

02.04.2019 / 16:55
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

1. Angaben zu den Personen, die Führungsaufgaben wahrnehmen, sowie zu den in enger Beziehung zu ihnen stehenden Personen

a) Name

Name und Rechtsform:

Armin M. Kessler and Ann C. Kessler Family Trust

2. Grund der Meldung

a) Position / Status

Person steht in enger Beziehung zu:
Titel:
Vorname:	Ann Clare
Nachname(n):	Kessler
Position:	Aufsichtsrat

b) Erstmeldung

3. Angaben zum Emittenten, zum Teilnehmer am Markt für Emissionszertifikate, zur Versteigerungsplattform, zum Versteigerer oder zur Auktionsaufsicht

a) Name

Epigenomics AG

b) LEI

549300X1C4U862NDLN97

4. Angaben zum Geschäft/zu den Geschäften

a) Beschreibung des Finanzinstruments, Art des Instruments, Kennung

Art:	Aktie
ISIN:	DE000A11QW50

b) Art des Geschäfts

Kauf

c) Preis(e) und Volumen

Preis(e)	Volumen
2,0588 USD	1445,28 USD
2,0100 USD	48541,50 USD

d) Aggregierte Informationen

Preis	Aggregiertes Volumen
2,0114 USD	49986,78 USD

e) Datum des Geschäfts

2019-03-29; UTC+2

f) Ort des Geschäfts

Außerhalb eines Handelsplatzes

02.04.2019 Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de

Sprache:	Deutsch
Unternehmen:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Deutschland
Internet:	www.epigenomics.com


Ende der Mitteilung	DGAP News-Service

29. März 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

29.03.2019 / 16:47
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

25 March 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	3.34 %	0.09 %	3.44 %	36021540
Previous notification	0.00 %	0.09 %	0.09 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1204657	0.00 %	3.34 %
Total	1204657		3.34 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	33619	0.09 %
		Total	33619	0.09 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	3.34 %	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

29 March 2019

29.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

News & Investoren

Archive

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: CMS akzeptiert Epigenomics‘ Antrag auf NCD-Überprüfung

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP-DD: Epigenomics AG deutsch

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Archiv

News-Kategorien

Medienkontakt